---
title: "Chronic Kidney Disease Prevalence and Management in Irish Primary Care (CRADLE EHR Study)"
id: "medrxiv-1-prevalence-and-management-of-chronic-kidney-disease-in-irish-primary-care"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-1-prevalence-and-management-of-chronic-kidney-disease-in-irish-primary-care"
content_type: "clinical_feed_article"
specialty: "Nephrology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.27.26366639v1?rss=1"
published_at: "2026-10-29T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Chronic Kidney Disease Prevalence and Management in Irish Primary Care (CRADLE EHR Study)
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-1-prevalence-and-management-of-chronic-kidney-disease-in-irish-primary-care
- **Specialty:** [Nephrology](https://medichelpline.com/clinical-feed/nephrology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.27.26366639v1?rss=1)
- **Published At:** 2026-10-29T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- A retrospective cohort drawn from the CRADLE electronic health record network examined adults aged ≥20 years active on 30 July 2025 across 66 Irish practices. - Investigators identified 19,382 laboratory-confirmed **CKD** cases among 468,534 adults, yielding an age- and sex-standardised prevalence of 5.36% in this primary care population. - The cohort had a high comorbidity burden: 74.0% had at least one cardiometabolic comorbidity, which shapes risk and management priorities in primary care. - Kidney function monitoring improved over time: within 12 months of laboratory-confirmed **CKD**, 66.0% received a follow-up **eGFR** test according to the study team’s descriptive analyses. - Albuminuria testing remained low overall: 15.1% of patients had a **uACR** test within 12 months, and that rate dropped to 6.6% among patients without type 2 diabetes (T2DM). - Among patients eligible for guideline-directed medical therapy (GDMT), 64.0% received any **RAASi** after meeting prescription eligibility, while 30.9% received any **SGLT2i** after becoming eligible. - Use of **SGLT2i** was substantially lower (9.4%) in patients without T2DM or heart failure, a subgroup in which uptake lagged. - The authors reported that datasets are not publicly available; data access requires request to the corresponding author and governance approvals. - Ethical approval was obtained from the Irish College of General Practitioners Research Ethics Committee (Reference: 2682); three authors declared employment with Boehringer Ingelheim. - The study team noted persistent gaps: low albuminuria testing especially in non-diabetic patients, and suboptimal GDMT uptake, which represent concrete targets for primary-care improvement efforts.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=kgxjz8W..pzr2SsXvrhwuPo7G7bZ7a7jdhWjt1rkEAg-1793330846.5869427-1.2.1.1-m.wgZIyMX8BkZF94DrMO1jX2.i2em2rOfuFb57W5V._7OY3I9L6VwJ6Y35ocB9P3) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.10.27.26366639v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Prevalence and Management of Chronic Kidney Disease in Irish Primary Care Network [ View ORCID Profile](http://orcid.org/0000-0003-1119-064X)Benjamin M Jacob, Keelan Eyers, [ View ORCID Profile](http://orcid.org/0000-0002-1368-0434)Danyao Jin, Michael Hayes, Aoife Coughlan, Emma Ryan, Benjamin van Hecke, Patrick Redmond, Austin G. Stack, Donal J Sexton, Donal Bailey doi: https://doi.org/10.64898/2026.10.27.26366639 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Benjamin M Jacob 1 Centric Health, Dublin, Ireland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Benjamin%2BM%2BJacob%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Jacob%20BM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABenjamin%2BM%2BJacob%2B) * [ORCID record for Benjamin M Jacob](http://orcid.org/0000-0003-1119-064X "Open in new tab") * For correspondence: benjamin.jacob@centrichealth.ie Keelan Eyers 1 Centric Health, Dublin, Ireland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Keelan%2BEyers%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Eyers%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKeelan%2BEyers%2B) Danyao Jin 2 Boehringer Ingelheim Ltd, Bracknell, UK; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Danyao%2BJin%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Jin%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADanyao%2BJin%2B) * [ORCID record for Danyao Jin](http://orcid.org/0000-0002-1368-0434 "Open in new tab") Michael Hayes 3 Trinity College Dublin, Dublin, Ireland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Michael%2BHayes%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hayes%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMichael%2BHayes%2B) Aoife Coughlan 1 Centric Health, Dublin, Ireland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Aoife%2BCoughlan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Coughlan%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAoife%2BCoughlan%2B) Emma Ryan 2 Boehringer Ingelheim Ltd, Bracknell, UK; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Emma%2BRyan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ryan%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEmma%2BRyan%2B) Benjamin van Hecke 2 Boehringer Ingelheim Ltd, Bracknell, UK; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Benjamin%2Bvan%2BHecke%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=van%20Hecke%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABenjamin%2Bvan%2BHecke%2B) Patrick Redmond 4 Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Patrick%2BRedmond%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Redmond%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APatrick%2BRedmond%2B) Austin G. Stack 5 University of Limerick, Limerick, Ireland * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Austin%2BG.%2BStack%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Stack%20AG&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAustin%2BG.%2BStack%2B) Donal J Sexton 3 Trinity College Dublin, Dublin, Ireland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Donal%2BJ%2BSexton%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sexton%20DJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADonal%2BJ%2BSexton%2B) Donal Bailey 1 Centric Health, Dublin, Ireland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Donal%2BBailey%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bailey%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADonal%2BBailey%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.10.27.26366639v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1334066/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.10.27.26366639v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1334066/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.10.27.26366639v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1334066/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.10.27.26366639v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1334066/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.10.27.26366639v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1334066/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.10.27.26366639v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1334066/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: Chronic kidney disease (CKD) imposes a substantial burden on health systems and society. Although early detection and guideline-recommended management can improve outcomes, opportunities remain to enhance management in primary care. Aim: To evaluate CKD prevalence, guideline-directed medical therapy (GDMT), and monitoring in Irish primary care. Design and Setting: Retrospective cohort study using community-based electronic health records (EHR) from the CRADLE database, across 66 Irish practices. Methods: Active adults aged ≥20 years on 30 July 2025 were included. CKD prevalence was determined using estimated glomerular filtration rate (eGFR) and/or urine albumin-to-creatinine ratio (uACR). Descriptive analyses of epidemiology, prescribing, and monitoring were conducted. Results: Of 468,534 adults, 19,382 met the criteria of laboratory-confirmed CKD: age- and sex-standardised prevalence was 5.36%. 74.0% of laboratory-confirmed CKD patients have ≥1 cardiometabolic comorbidities. Within 12 months of laboratory-confirmed CKD, monitoring increased over time, with 66.0% of patients receiving follow-up eGFR test and 15.1% receiving uACR test, falling to 6.6% among patients without type 2 diabetes (T2DM). Among GDMT-eligible CKD patients, 64.0% received any renin-angiotensin-aldosterone inhibitors (RAASi) and 30.9% received any sodium-glucose cotransporter 2 inhibitors (SGLT2i) after they met their prescription eligibility for CKD, but SGLT2i use dropped to 9.4% among those without T2DM or heart failure. Conclusion: CKD and cardiometabolic comorbidities impose a substantial burden in Irish primary care. Despite improved kidney function testing, albuminuria testing remained low, particularly in non-diabetic patients, and GDMT use was suboptimal. Improving albuminuria testing and timely GDMT offers important opportunities to improve CKD outcomes in Irish primary care. ### Competing Interest Statement DJ, ER and BVH are employees of Boehringer Ingelheim. The remaining authors declare that they have no competing interests. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee/IRB of the Irish College of General Practitioners Research Ethics Committee gave ethical approval for this work (Reference: 2682) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The datasets analysed during the current study are not publicly available. Access to the data may be available from the corresponding author on reasonable request and with permission from the relevant data custodians, subject to applicable governance and approval processes. ## Funder Information Declared Boehringer Ingelheim (United Kingdom), https://ror.org/01jnnpe14 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.10.27.26366639v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.10.28.26366759v1 "Lesion selection and external evaluation of clinical-imaging survival models after transarterial chemoembolization for hepatocellular carcinoma")[Next ](https://www.medrxiv.org/content/10.64898/2026.10.28.26366683v1 "Maintaining EHR-based Predictive Clinical Decision Support in Mental Health against Temporal Shifts") Posted October 29, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.10.27.26366639v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/10/29/2026.10.27.26366639.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.10.27.26366639v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.10.27.26366639v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/10/29/2026.10.27.26366639.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Prevalence and Management of Chronic Kidney Disease in Irish Primary Care Network Benjamin M Jacob, Keelan Eyers, Danyao Jin, Michael Hayes, Aoife Coughlan, Emma Ryan, Benjamin van Hecke, Patrick Redmond, Austin G. Stack, Donal J Sexton, Donal Bailey medRxiv 2026.10.27.26366639; doi: https://doi.org/10.64898/2026.10.27.26366639 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.27.26366639v1%26text%3DPrevalence%2520and%2520Management%2520of%2520Chronic%2520Kidney%2520Disease%2520in%2520Irish%2520Primary%2520Care%2520Network "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.27.26366639v1%26t%3DPrevalence%2520and%2520Management%2520of%2520Chronic%2520Kidney%2520Disease%2520in%2520Irish%2520Primary%2520Care%2520Network "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.27.26366639v1%26title%3DPrevalence%2520and%2520Management%2520of%2520Chronic%2520Kidney%2520Disease%2520in%2520Irish%2520Primary%2520Care%2520Network%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.27.26366639v1%26title%3DPrevalence%2520and%2520Management%2520of%2520Chronic%2520Kidney%2520Disease%2520in%2520Irish%2520Primary%2520Care%2520Network "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.10.27.26366639) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.10.27.26366639v1&count=horizontal&via=&text=Prevalence%20and%20Management%20of%20Chronic%20Kidney%20Disease%20in%20Irish%20Primary%20Care%20Network&counturl=www.medrxiv.org/content/10.64898/2026.10.27.26366639v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (637) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (915) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (348) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4966) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (493) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (426) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (674) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1679) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16197) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (36) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1238) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7245) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (751) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1092) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5257) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1463) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1823) * [Hematology](https://www.medrxiv.org/collection/hematology) (599) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1375) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16457) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1198) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (693) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (156) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (745) * [Neurology](https://www.medrxiv.org/collection/neurology) (7549) * [Nursing](https://www.medrxiv.org/collection/nursing) (377) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1119) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1292) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1037) * [Oncology](https://www.medrxi
## Related Clinical Research

- [Prevalence, risk factors, and renoprotective treatment gaps in chronic kidney disease among tertia](https://medichelpline.com/clinical-feed/bmj-open-9-prevalence-risk-factors-and-renoprotective-treatment-of-chronic-kidney-disease.md)
- [Semaglutide Lowers Risk of COVID-19 and Serious Infections in FLOW Trial Participants with T2D and](https://medichelpline.com/clinical-feed/pubmed-41728915.md) (DOI: 10.1093/ndt/gfag036)
- [Blood methylation profile stratifies 10-year risk for 21 common diseases](https://medichelpline.com/clinical-feed/medrxiv-20-one-blood-methylation-profile-stratifies-ten-year-risk-across-21-common-diseases.md)
- [Embolic Stroke and DOAC Failure in Libman-Sacks Endocarditis with Antiphospholipid Syndrome](https://medichelpline.com/clinical-feed/pubmed-43058350.md) (DOI: 10.1007/s00296-026-06331-w)
- [ZEUS trial: IL-6 blocker ziltivekimab lowered inflammation but did not cut major CV events](https://medichelpline.com/clinical-feed/aha-news-1-researchers-say-inflammation-as-a-treatment-target-still-important-despite.md)

## Navigation
- [← Back to Nephrology Feed](https://medichelpline.com/clinical-feed/nephrology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.